California State Teachers Retirement System decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 9.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 243,401 shares of the life sciences company’s stock after selling 24,900 shares during the quarter. California State Teachers Retirement System owned about 0.17% of Illumina worth $48,485,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ILMN. Global X Management Co. LLC lifted its holdings in shares of Illumina by 84.2% in the second quarter. Global X Management Co. LLC now owns 2,360 shares of the life sciences company’s stock valued at $410,000 after buying an additional 1,079 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of Illumina by 5.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 484,721 shares of the life sciences company’s stock valued at $84,109,000 after purchasing an additional 24,459 shares during the last quarter. Advisors Asset Management Inc. lifted its holdings in shares of Illumina by 80.2% during the second quarter. Advisors Asset Management Inc. now owns 15,132 shares of the life sciences company’s stock valued at $2,626,000 after purchasing an additional 6,735 shares during the last quarter. LMR Partners LLP purchased a new stake in shares of Illumina during the second quarter valued at $1,170,000. Finally, Legal & General Group Plc lifted its holdings in shares of Illumina by 2.5% during the second quarter. Legal & General Group Plc now owns 667,874 shares of the life sciences company’s stock valued at $115,892,000 after purchasing an additional 16,560 shares during the last quarter. Institutional investors and hedge funds own 91.75% of the company’s stock.

Illumina, Inc. (ILMN) opened at $210.85 on Friday. The firm has a market capitalization of $31,045.44, a price-to-earnings ratio of 62.17, a P/E/G ratio of 3.51 and a beta of 0.79. Illumina, Inc. has a 52-week low of $125.68 and a 52-week high of $230.72. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. Illumina’s quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.97 earnings per share. equities analysts predict that Illumina, Inc. will post 3.75 EPS for the current fiscal year.

In other Illumina news, Director Robert S. Epstein sold 1,250 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $226.55, for a total value of $283,187.50. Following the transaction, the director now directly owns 9,088 shares of the company’s stock, valued at approximately $2,058,886.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $212.55, for a total value of $4,251,000.00. Following the completion of the transaction, the director now directly owns 505,980 shares in the company, valued at $107,546,049. The disclosure for this sale can be found here. Insiders have sold 136,421 shares of company stock worth $28,489,101 over the last three months. 0.89% of the stock is owned by insiders.

Several brokerages have recently commented on ILMN. Morgan Stanley upped their target price on Illumina from $122.00 to $135.00 and gave the company an “underweight” rating in a report on Thursday. Goldman Sachs Group reaffirmed a “neutral” rating and set a $200.00 target price on shares of Illumina in a report on Tuesday, September 26th. BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Canaccord Genuity reaffirmed a “buy” rating and set a $230.00 target price (up from $215.00) on shares of Illumina in a report on Thursday, October 12th. Finally, Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $252.00 target price for the company in a report on Tuesday, December 5th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company. Illumina currently has an average rating of “Buy” and a consensus price target of $202.60.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/illumina-inc-ilmn-shares-sold-by-california-state-teachers-retirement-system/1764988.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.